References
-
1.
Alzheimer's Association. 2015 Alzheimer's disease facts and figures. Alzheimer's & Dementia. 2015;11(3):332-84.
-
2.
Drummond E, Wisniewski T. Alzheimer’s disease: experimental models and reality. Acta neuropathologica. 2017;133(2):155-75.
-
3.
van der Staay FJ, Arndt SS, Nordquist RE. Evaluation of animal models of neurobehavioral disorders. Behavioral and Brain Functions. 2009;5(1):11.
-
4.
Zuluaga AF, Rodriguez CA, Agudelo M, Vesga O. About the validation of animal models to study the pharmacodynamics of generic antimicrobials. Clinical infectious diseases. 2014;59(3):459-61.
-
5.
Varga OE, Hansen AK, Sandøe P, Olsson IAS. Validating animal models for preclinical research: a scientific and ethical discussion. Alternatives to Laboratory Animals. 2010;38(3):245-8.
-
6.
Claeysen S, Bockaert J, Giannoni P. Serotonin: a new hope in Alzheimer’s disease? ACS Chem Neurosci. 2015;6(7):940-3.
-
7.
Metaxas A, Anzalone M, Vaitheeswaran R, Petersen S, Landau AM, Finsen B. Neuroinflammation and amyloid-beta 40 are associated with reduced serotonin transporter (SERT) activity in a transgenic model of familial Alzheimer’s disease. Alzheimer's research & therapy. 2019;11(1):38.
-
8.
Noristani HN, Olabarria M, Verkhratsky A, Rodriguez JJ. Serotonin fibre sprouting and increase in serotonin transporter immunoreactivity in the CA1 area of hippocampus in a triple transgenic mouse model of Alzheimer’s disease. European Journal of Neuroscience. 2010;32(1):71-9.
-
9.
Liu Y, Yoo M, Savonenko A, Stirling W, Price DL, Borchelt DR, et al. Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimer's disease. Journal of Neuroscience. 2008;28(51):13805-14.
-
10.
Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain research reviews. 2008;59(1):201-20.